Mark K Buyyounouski

Summary

Affiliation: Fox Chase Cancer Center
Country: USA

Publications

  1. doi request reprint A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Brachytherapy 11:299-305. 2012
  2. doi request reprint Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer
    Mark K Buyyounouski
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 30:1857-63. 2012
  3. doi request reprint Radiotherapy: PSA nadir predicts long-term mortality
    Mark K Buyyounouski
    Clinical Research, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Nat Rev Clin Oncol 7:188-90. 2010
  4. ncbi request reprint Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:59-66. 2008
  5. ncbi request reprint Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
  6. pmc Prostate bed motion during intensity-modulated radiotherapy treatment
    Tracy Klayton
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Int J Radiat Oncol Biol Phys 84:130-6. 2012
  7. pmc A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 71:338-45. 2008
  8. doi request reprint Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer
    Navesh K Sharma
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 80:437-44. 2011
  9. pmc Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 110:68-80. 2007
  10. ncbi request reprint The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004

Detail Information

Publications47

  1. doi request reprint A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Brachytherapy 11:299-305. 2012
    ....
  2. doi request reprint Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer
    Mark K Buyyounouski
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Clin Oncol 30:1857-63. 2012
    ..To validate the interval to biochemical failure (IBF) as a prognostic factor at the time of biochemical failure for prostate cancer mortality (PCM) following radiotherapy (RT)...
  3. doi request reprint Radiotherapy: PSA nadir predicts long-term mortality
    Mark K Buyyounouski
    Clinical Research, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111 2497, USA
    Nat Rev Clin Oncol 7:188-90. 2010
    ..5 ng/ml within 2 years of radiotherapy treatment predicts distant metastases and death from prostate cancer...
  4. ncbi request reprint Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 70:59-66. 2008
    ..The present study examined the clinical utility of the interval to biochemical failure (IBF) as a prognostic factor for distant metastasis (DM) and prostate cancer-specific mortality (PCSM) after radiotherapy...
  5. ncbi request reprint Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 63:1455-62. 2005
    ..To compare several characteristics of alternative definitions of biochemical failure (BF) in men with extended follow-up after radiotherapy (RT) with or with androgen deprivation therapy (ADT) for prostate cancer...
  6. pmc Prostate bed motion during intensity-modulated radiotherapy treatment
    Tracy Klayton
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Int J Radiat Oncol Biol Phys 84:130-6. 2012
    ..In this series, we report prostate bed localization and motion characteristics, using data collected from implanted radiofrequency transponders...
  7. pmc A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 71:338-45. 2008
    ..To compare the toxicity and biochemical outcomes of intensity-modulated radiation therapy (IMRT) and (125)I transperineal permanent prostate seed implant ((125)I) for patients with low-risk prostate cancer...
  8. doi request reprint Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer
    Navesh K Sharma
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 80:437-44. 2011
    ..The present study compared the genitourinary and gastrointestinal (GI) toxicity in men treated with 3D-CRT+AD vs. IMRT+AD...
  9. pmc Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 110:68-80. 2007
    ..The authors hypothesized that early failures due to subclinical micrometastasis at presentation could be differentiated from late failures due to local persistence...
  10. ncbi request reprint The radiation doses to erectile tissues defined with magnetic resonance imaging after intensity-modulated radiation therapy or iodine-125 brachytherapy
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 59:1383-91. 2004
    ....
  11. pmc Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer
    Niraj Pahlajani
    Department of Radiation Oncology, Cooper University Hospital, Camden, NJ, USA
    Int J Radiat Oncol Biol Phys 82:1949-56. 2012
    ..However, local failure is also a major problem. We sought to establish the importance of more aggressive local radiotherapy (RT) to ≥80 Gy...
  12. doi request reprint Hypoxic prostate/muscle PO2 ratio predicts for outcome in patients with localized prostate cancer: long-term results
    Aruna Turaka
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 82:e433-9. 2012
    ..To correlate tumor oxygenation status with long-term biochemical outcome after prostate brachytherapy...
  13. pmc Radiation dose and late failures in prostate cancer
    Peter B Morgan
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497, USA
    Int J Radiat Oncol Biol Phys 67:1074-81. 2007
    ..To quantify the impact of radiation dose escalation on the timing of biochemical failure (BF) and distant metastasis (DM) for prostate cancer treated with radiotherapy (RT) alone...
  14. pmc How can men destined for biochemical failure after androgen deprivation and radiotherapy be identified earlier?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 70:1487-91. 2008
    ..This study sought to determine whether the initial PSA increase from undetectable after completion of all treatment predicts for eventual biochemical failure (BF)...
  15. ncbi request reprint The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 67:1082-7. 2007
    ..To investigate the prognostic utility of the proportion of prostate biopsy tissue containing Gleason pattern 4 or 5 (GP4/5) after definitive radiotherapy (RT) for prostate cancer...
  16. pmc Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer
    Alan Pollack
    Alan Pollack, Gail Walker, and Radka Stoyanova, University of Miami Miller School of Medicine, Miami, FL Eric M Horwitz, Robert Price, Richard E Greenberg, Robert G Uzzo, Charlie Ma, and Mark K Buyyounouski, Fox Chase Cancer Center, Philadelphia, PA Steven Feigenberg, University of Maryland, Baltimore, MD Andre A Konski, Wayne State University Medical Center and Benjamin Movsas, Henry Ford Hospital, Detroit, MI
    J Clin Oncol 31:3860-8. 2013
    ..To determine if escalated radiation dose using hypofractionation significantly reduces biochemical and/or clinical disease failure (BCDF) in men treated primarily for prostate cancer...
  17. pmc A novel method for predicting late genitourinary toxicity after prostate radiation therapy and the need for age-based risk-adapted dose constraints
    Awad A Ahmed
    Temple University School of Medicine, Philadelphia, Pennsylvania, USA
    Int J Radiat Oncol Biol Phys 86:709-15. 2013
    ..The area under the histogram curve (AUHC) was also analyzed...
  18. doi request reprint Gains from real-time tracking of prostate motion during external beam radiation therapy
    Jin sheng Li
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Int J Radiat Oncol Biol Phys 75:1613-20. 2009
    ..To study the gains from real-time tracking of prostate motion and threshold-based intervention and the feasibility of margin reduction for external beam radiation therapy of prostate cancer...
  19. ncbi request reprint Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 61:1291-8. 2005
    ..The temporal kinetics of posttreatment PSA levels was examined to define the error in the classification of BF...
  20. pmc Does treatment duration affect outcome after radiotherapy for prostate cancer?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 72:1402-7. 2008
    ..In prostate cancer, the overall treatment time can be considerable, as can the potential for treatment breaks. We evaluated the effect of elapsed treatment time on outcome after RT for prostate cancer...
  21. pmc Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Cancer 109:2011-5. 2007
    ..This case series of 6 patients is the first to report the outcome of ductal carcinoma treated with external beam radiotherapy...
  22. doi request reprint The impact of dose-escalated radiotherapy plus androgen deprivation for prostate cancer using 2 linked nomograms
    Radka Stoyanova
    Department of Radiation Oncology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    Cancer 119:1080-8. 2013
    ..The authors designed a model to estimate the results of various doses of radiotherapy (RT) combined with various durations of ADT...
  23. pmc Assessment of the American Joint Committee on Cancer staging (sixth and seventh editions) for clinically localized prostate cancer treated with external beam radiotherapy and comparison with the National Comprehensive Cancer Network risk-stratification me
    Nicholas G Zaorsky
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 118:5535-43. 2012
    ....
  24. pmc Aspirin and statin nonuse associated with early biochemical failure after prostate radiation therapy
    Nicholas G Zaorsky
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Int J Radiat Oncol Biol Phys 84:e13-7. 2012
    ..To present the largest retrospective series investigating the effect of aspirin and statins, which are hypothesized to have antineoplastic properties, on biochemical failure (nadir plus 2 ng/mL) after prostate radiation therapy (RT)...
  25. pmc What dose of external-beam radiation is high enough for prostate cancer?
    Thomas N Eade
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 68:682-9. 2007
    ..To quantify the radiotherapy dose-response of prostate cancer, adjusted for prognostic factors in a mature cohort of men treated relatively uniformly at a single institution...
  26. pmc Evaluation of the Prostate Cancer Prevention Trial Risk calculator in a high-risk screening population
    David J Kaplan
    Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, USA
    BJU Int 105:334-7. 2010
    ..Study Type - Diagnostic (exploratory cohort) Level of Evidence 2b...
  27. pmc Residual prostate cancer after radiotherapy: a study of radical cystoprostatectomy specimens
    David J Kaplan
    Department of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 72:654-8. 2008
    ..We investigated the relationship between prostate-specific antigen (PSA) and histologically residual CaP after definitive RT in patients undergoing radical cystoprostatectomy (RCP) for unrelated indications...
  28. ncbi request reprint The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer
    Matthew C Abramowitz
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
    Cancer 112:55-60. 2008
    ..The objective of the current study was to compare ASTRO and Phoenix BF estimates as determinants of distant metastasis (DM), cause-specific mortality (CSM), and overall mortality (OM)...
  29. doi request reprint Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 71:938-41. 2008
    ..The purpose of this study was to determine whether a history of TURP is associated with increased biochemical failure (BF) after definitive radiotherapy for prostate cancer...
  30. pmc Young age under 60 years is not a contraindication to treatment with definitive dose escalated radiotherapy for prostate cancer
    Tracy L Klayton
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia 19111, United States
    Radiother Oncol 101:508-12. 2011
    ..It is widely believed that younger prostate cancer patients are at greater risk of recurrence following radiotherapy (RT)...
  31. pmc Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer
    Jeff M Michalski
    Department of Radiation Oncology, Washington University School of Medicine, St Louis, MO 63110, USA
    Int J Radiat Oncol Biol Phys 76:361-8. 2010
    ..To define a prostate fossa clinical target volume (PF-CTV) for Radiation Therapy Oncology Group (RTOG) trials using postoperative radiotherapy for prostate cancer...
  32. doi request reprint Reduction of prostate intrafractional motion from shortening the treatment time
    Jin sheng Li
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Phys Med Biol 58:4921-32. 2013
    ..The intrafractional motion effects on prostate treatment are significantly smaller and the required margins can be therefore reduced when the treatment is shortened. ..
  33. pmc Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
    Alan Pollack
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Int J Radiat Oncol Biol Phys 64:518-26. 2006
    ..The dosimetry and acute toxicity are described in the first 100 men enrolled in a randomized trial...
  34. ncbi request reprint Gleason scoring at a comprehensive cancer center: what's the difference?
    Natasha C Townsend
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    J Natl Compr Canc Netw 11:812-9. 2013
    ..74). Changes in GS were common and the GS assigned by a comprehensive cancer center provided better BF risk stratification and prognostication for patients. Changes in GS may impact treatment recommendations in 9% to 26% of patients. ..
  35. ncbi request reprint Intensity-modulated radiotherapy with MRI simulation to reduce doses received by erectile tissue during prostate cancer treatment
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 58:743-9. 2004
    ..This is the first description of the ability to limit the dose received by the penile bulb (PB) and corporal bodies (CB) using intensity-modulated radiotherapy (IMRT)...
  36. ncbi request reprint Positive prostate biopsy laterality and implications for staging
    Mark K Buyyounouski
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
    Urology 62:298-303. 2003
    ..Prostate biopsy laterality status (unilateral versus bilateral positive) is part of clinical staging using American Joint Commission on Cancer criteria, but is rarely used...
  37. doi request reprint An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy
    Navesh K Sharma
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Brachytherapy 9:126-30. 2010
    ....
  38. doi request reprint Radiotherapy treatment planning for testicular seminoma
    Richard B Wilder
    Department of Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA
    Int J Radiat Oncol Biol Phys 83:e445-52. 2012
    ..g., if they have a horseshoe kidney, inflammatory bowel disease, or a history of radiotherapy)...
  39. pmc Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death
    Pino Alcantara
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA
    Cancer 109:41-7. 2007
    ..0001).CONCLUSIONS.nPSA12 is a strong independent predictor of outcome after RT alone for prostate cancer and should be useful in identifying patients at high risk for progression to metastasis and death...
  40. ncbi request reprint Unexpected dementia following prophylactic cranial irradiation for small cell lung cancer: case report
    David J D'Ambrosio
    Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
    J Neurooncol 85:77-9. 2007
    ..Prophylactic cranial irradiation (PCI) is commonly offered to patients with limited stage primary small cell lung cancer following a complete response...
  41. pmc Stamp test delivers message on erectile dysfunction after high-dose intensity-modulated radiotherapy for prostate cancer
    Lanea M M Keller
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Urology 80:337-42. 2012
    ..To evaluate erectile function after high-dose radiotherapy for prostate cancer using the International Index of Erectile Function, Expanded Prostate Cancer Index Composite, and stamp test...
  42. doi request reprint Radiation therapy for pituitary metastasis: report of four cases
    Aruna Turaka
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Tumori 98:e1-6. 2012
    ..To report the clinical outcomes of four patients with pituitary metastases treated with radiotherapy...
  43. doi request reprint Effect of gold marker seeds on magnetic resonance spectroscopy of the prostate
    Murshed Hossain
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    Int J Radiat Oncol Biol Phys 83:451-8. 2012
    ..The purpose of this study was to quantify the effects of gold seeds on the quality of MRSI data acquired in phantom experiments...
  44. doi request reprint Dosimetric comparison of stereotactic body radiotherapy using 4D CT and multiphase CT images for treatment planning of lung cancer: evaluation of the impact on daily dose coverage
    Lu Wang
    Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Radiother Oncol 91:314-24. 2009
    ..To investigate the dosimetric impact of using 4D CT and multiphase (helical) CT images for treatment planning target definition and the daily target coverage in hypofractionated stereotactic body radiotherapy (SBRT) of lung cancer...
  45. ncbi request reprint Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performance
    Scott G Williams
    Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
    Int J Radiat Oncol Biol Phys 70:1169-75. 2008
    ..To define and incorporate the impact of the percentage of positive biopsy cores (PPC) into a predictive model of prostate cancer radiotherapy biochemical outcome...
  46. ncbi request reprint In regard to Selek et al. erectile dysfunction and radiation dose to penile base structures: a lack of correlation. IJROBP 2004;59:1039-1046
    Mark K Buyyounouski
    Int J Radiat Oncol Biol Phys 60:1664-5; author reply 1666. 2004
  47. ncbi request reprint Re: improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the search database
    Mark K Buyyounouski
    J Urol 171:1246-7; author reply 1247. 2004